Drug
Olaparib clinical trials
Also written AZD2281, Lynparza and KU-0059436.
- studies test it
- 338
- open now
- 61
- in phase 3
- 37
- first study started
- 2005
Keep track of what changes. Save the olaparib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Lynparza
- 157
Development codes
- AZD2281
- 186
- KU-0059436
- 122
Studies by the year they started
336 studies that test it; most in 2018 (39); 1 more planned to start later
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 6 |
| 2008 | 10 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 7 |
| 2013 | 8 |
| 2014 | 13 |
| 2015 | 12 |
| 2016 | 26 |
| 2017 | 25 |
| 2018 | 39 |
| 2019 | 38 |
| 2020 | 34 |
| 2021 | 27 |
| 2022 | 27 |
| 2023 | 19 |
| 2024 | 18 |
| 2025 | 11 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 10
- Phase 1
- 103
- Phase 2
- 210
- Phase 3
- 37
- Phase 4
- 5
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 85 · Other 253
AstraZeneca (59) · National Cancer Institute (NCI) (40) · Merck Sharp & Dohme LLC (11) · M.D. Anderson Cancer Center (10) · Memorial Sloan Kettering Cancer Center (7) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (7) · Dana-Farber Cancer Institute (6) · The Netherlands Cancer Institute (6)
Often tested with
Tested in the same studies.
Durvalumab (40) · Pembrolizumab (35) · Cediranib (19) · Carboplatin (16) · Paclitaxel (15) · Bevacizumab (14) · Palbociclib (14) · Ceralasertib (13)
Studies
Open first, then newest update. How each study uses olaparib is read from its arms, and is right about nine times in ten.
Testing it · 338
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationRecruitingPhase 2National Cancer Institute (NCI)NCT04858334Written as Olaparib
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingPhase 3Merck Sharp & Dohme LLCNCT03486873Written as Olaparib
- Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)RecruitingPhase 1/2National Cancer Institute (NCI)NCT04086485Written as Olaparib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Olaparib
- Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell TumorsNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07850973Written as Olaparib
- WIRE - Novel Treatments in Renal Cell CancerRecruitingPhase 2CCTU- Cancer ThemeNCT03741426Written as Olaparib
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535Written as Olaparib (CLOSED TO ENROLLMENT)
- Carboplatin or Olaparib for BRcA Deficient Prostate CancerRecruitingPhase 2VA Office of Research and DevelopmentNCT04038502Written as Olaparib
- Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerRecruitingPhase 1National Cancer Institute (NCI)NCT04633239Written as Olaparib
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerRecruitingPhase 1National Cancer Institute (NCI)NCT04585958Written as Olaparib
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690Written as Olaparib
- Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerRecruitingPhase 1Dana-Farber Cancer InstituteNCT06488378Written as Olaparib
- Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP LossRecruitingPhase 1M.D. Anderson Cancer CenterNCT07382544Written as Olaparib
- Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerRecruitingPhase 3NRG OncologyNCT06580314Written as Olaparib
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001Written as Olaparib (300 mg BID)
- Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerRecruitingPhase 1University of Colorado, DenverNCT06856499Written as Olaparib
- Pembro With Radiation With or Without OlaparibRecruitingPhase 2Zin W MyintNCT05568550Written as Olaparib
- An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibRecruitingPhase 2University of Colorado, DenverNCT05887609Written as Olaparib
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Olaparib
- Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic CancerRecruitingPhase 2Cambridge University Hospitals NHS Foundation TrustNCT05093231Written as Olaparib
See all 338 studies that test olaparib →
Given in every arm · 49 — olaparib is usual care beside what is tested
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06353386Written as Olaparib
- Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)RecruitingPhase 1/2Artios Pharma LtdNCT05898399Written as Olaparib
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06966700Written as Olaparib
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerRecruitingPhase 3ImunonNCT06915025Written as Olaparib
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesRecruitingPhase 2AbbVieNCT07024784Written as Olaparib
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04090567Written as Olaparib
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06797635Written as Olaparib
- Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast CancerRecruitingPhase 1Immunomic Therapeutics, Inc.NCT07652242Written as Olaparib
- Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT06298084Written as Olaparib
- PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06245889Written as Olaparib
- A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate CancerNot yet recruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07641855Written as Olaparib
- Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid TumorsRecruitingPhase 1MOMA TherapeuticsNCT06545942Written as Olaparib
- Pembrolizumab, Olaparib, and Temozolomide for People With GliomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05188508Written as Olaparib and Temozolomide
- Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and DurvalumabRecruitingPhase 2Fondazione Ricerca TraslazionaleNCT05568212Written as Olaparib tablet
- WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCRecruitingPhase 2AGO Research GmbHNCT04644289Written as olaparib
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsRecruitingPhase 1ExelixisNCT05932862Written as Olaparib
- Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 InhibitorRecruitingPhase 2Seoul National University HospitalNCT05536128Written as Olaparib
- Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based ChemotherapyRecruitingPhase 2Asan Medical CenterNCT05222971Written as Olaparib
- EIS-12656 as Single Agent and in Combination in Patients With Specified Solid TumorsRecruitingPhase 1/2Eisbach Bio GmbHNCT06525298Written as Olaparib
- Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectivenessRecruitingPhase 4Radboud University Medical CenterNCT05078671Written as Olaparib
Showing 20 of 49.
Codes
What other systems call olaparib · ClinicalTrials.gg INT005326
- MeSH (NLM) C531550olaparibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) WOH1JD9AR8OLAPARIBConfirmed FDA, NLM, Wikidata
- RxNorm 1597582Confirmed FDA, Wikidata
- Wikidata Q7083106olaparibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71721OlaparibOne source FDA
- DrugBank DB09074One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531550 | olaparib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | WOH1JD9AR8 | OLAPARIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1597582 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7083106 | olaparib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71721 | Olaparib | One source FDA |
| DrugBank | DB09074 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.